Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Challenges in sexual medicine

Nature Reviews Urology volume 9, pages 537–542 (2012)Cite this article

Subjects

Abstract

The sexual medicine field has been in mode of revolution until recently. Like all other fields of biomedical research, the economic situation around the world has had a negative impact on the field's momentum—research funding bodies, regulatory bodies and pharmaceutical companies seem to have placed sexual medicine in their low-priority list. But this is not the only challenge the field is facing. The successful development of phosphodiesterase type 5 (PDE5) inhibitors for treatment of erectile dysfunction (ED) means that research in this area seems to have slowed. However, there remain several unmet medical needs within sexual medicine such as premature ejaculation, severe ED and hypoactive sexual desire disorder, which await novel therapeutic approaches. Despite these challenges, research into finding and developing such therapies is likely to continue in the sexual medicine field, in an effort to improve the lives of our patients, who wait for effective therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Schultheiss, D. & Glina, S. Highlights from the history of sexual medicine. J. Sex. Med. 7, 2031–2043 (2010).

    Article  Google Scholar 

  2. Sigusch, V. The birth of sexual medicine: Paolo Mantegazza as pioneer of sexual medicine in the 19th century. J. Sex. Med. 5, 217–222 (2008).

    Article  Google Scholar 

  3. Goldstein, I. Looking at sexual behaviour 60 years after Kinsey. J. Sex. Med. 7 (Suppl. 5), 246–247 (2010).

    Article  Google Scholar 

  4. Hayes, R. D. Circular and linear modelling of female sexual desire and arousal. J. Sex. Res. 48, 130–141 (2011).

    Article  Google Scholar 

  5. Lewis, R. W. G. History of the International Society of Sexual Medicine (ISSM)—the beginnings. J. Sex. Med. 5, 740–745 (2008).

    Article  Google Scholar 

  6. Parish, S. J. & Clayton, A. H. Sexual medicine education: review and commentary. J. Sex. Med. 4, 259–267 (2007).

    Article  Google Scholar 

  7. Platano, G., Margraf, J., Alder, J. & Bitzer, J. Psychosocial factors and therapeutic approaches in the context of sexual history taking in men: a study conducted among Swiss general practitioners and urologists. J. Sex. Med. 5, 2533–2556 (2008).

    Article  Google Scholar 

  8. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959–968 (2009).

    Article  CAS  Google Scholar 

  9. Arrowsmith, J. A decade of change. Nat. Rev. Drug Discov. 11, 17–18 (2012).

    Article  CAS  Google Scholar 

  10. Dunn, M. K. Timing of patent filing and market exclusivity. Nat. Rev. Drug Discov. 10, 487–488 (2011).

    Article  CAS  Google Scholar 

  11. Harrison, C. Patent watch: the patent cliff steepens. Nat. Rev. Drug Discov. 10, 12–13 (2011).

    Article  CAS  Google Scholar 

  12. Mullard, A. 2011 FDA drug approvals. Nat. Rev. Drug Discov. 11, 91–94 (2012).

    Article  CAS  Google Scholar 

  13. Paul, S. M. et al. How to improve R.& D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).

    Article  CAS  Google Scholar 

  14. Kola, I. The state of innovation in drug development. Clin. Pharmacol. Ther. 83, 227–230 (2008).

    Article  CAS  Google Scholar 

  15. Cohen, F. J. Macro trends in pharmaceutical innovation. Discov. Med. 5, 153–158 (2005).

    PubMed  Google Scholar 

  16. Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R.&D efficiency. Nat. Rev. Drug Discov. 11, 191–200 (2012).

    Article  CAS  Google Scholar 

  17. Fitzhenry, D. & Sandberg, L. Female sexual dysfunction. Nat. Rev. Drug Discov. 4, 99–100 (2005).

    Article  CAS  Google Scholar 

  18. McMurray, G., Casey, J. H. & Naylor, A. M. Animal models in urological disease and sexual dysfunction. Br. J. Pharmacol. 147 (Suppl. 2), S62–S79 (2006).

    Article  CAS  Google Scholar 

  19. Cellek, S., Foxwell, N. A. & Moncada, S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 52, 2353–2362 (2003).

    Article  CAS  Google Scholar 

  20. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004).

    Article  CAS  Google Scholar 

  21. Woodcock, J. & Woosley, R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59, 1–12 (2008).

    Article  CAS  Google Scholar 

  22. Lappin, G. et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther. 80, 203–215 (2006).

    Article  CAS  Google Scholar 

  23. Oosterhuis, B. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development. Bioanalysis 2, 377–379 (2010).

    Article  CAS  Google Scholar 

  24. Lewis, R. W. et al. Definitions/epidemiology/risk factors for sexual dysfunction. J. Sex. Med. 7, 1598–1607 (2010).

    Article  Google Scholar 

  25. Davis, S. R. et al. Testosterone for low libido in postmenopausal women not taking estrogen. N. Engl. J. Med. 359, 2005–2017 (2008).

    Article  CAS  Google Scholar 

  26. Moynihan, R. The marketing of a disease: female sexual dysfunction. BMJ 330, 192–194 (2005).

    Article  Google Scholar 

  27. Giraldi, A. Classifying female sexual dysfunction. In Cancer and Sexual Health (eds Mulhall, J. P., Incrocci, L., Goldstein, I. & Rosen, R.) 93–103 (Springer Science+Business Media, New York, 2011).

    Google Scholar 

  28. Hayes, R. D. Assessing female sexual dysfunction in epidemiological studies: why is it necessary to measure both low sexual function and sexually-related distress? Sex. Health 5, 215–218 (2008).

    Article  Google Scholar 

  29. Fugl-Meyer, A. R., Melin, R. & Fugl-Meyer, K. S. Life satisfaction in 18- to 64-year-old Swedes: in relation to gender, age, partner and immigrant status. J. Rehabil. Med. 34, 239–246 (2002).

    Article  Google Scholar 

  30. Shifren, J. L., Monz, B. U., Russo, P. A., Segreti, A. & Johannes, C. B. Sexual problems and distress in United States women: prevalence and correlates. Obstet. Gynecol. 112, 970–978 (2008).

    Article  Google Scholar 

  31. Basson, R. Pharmacotherapy for women's sexual dysfunction. Expert Opin. Pharmacother. 10, 1631–1648 (2009).

    Article  CAS  Google Scholar 

  32. Salonia, A. et al. Physiology of women's sexual function: basic knowledge and new findings. J. Sex. Med. 7, 2637–2660 (2010).

    Article  Google Scholar 

  33. Chivers, M. L. & Rosen, R. C. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? J. Sex. Med. 7, 858–872 (2010).

    Article  CAS  Google Scholar 

  34. Chivers, M. L., Seto, M. C., Lalumière, M. L., Laan, E. & Grimbos, T. Agreement of self-reported and genital measures of sexual arousal in men and women: a meta-analysis. Arch. Sex. Behav. 39, 5–56 (2010).

    Article  Google Scholar 

  35. Laan, E., Everaerd, W., van der Velde, J. & Geer, J. H. Determinants of subjective experience of sexual arousal in women: feedback from genital arousal and erotic stimulus content. Psychophysiology 32, 444–451 (1995).

    Article  CAS  Google Scholar 

  36. Both, S. et al. Unconscious classical conditioning of sexual arousal: evidence for the conditioning of female genital arousal to subliminally presented sexual stimuli. J. Sex. Med. 5, 100–109 (2008).

    Article  Google Scholar 

  37. Nurnberg, H. G. et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 300, 395–404 (2008).

    Article  CAS  Google Scholar 

  38. Wierman, M. E. et al. Endocrine aspects of women's sexual function. J. Sex. Med. 7, 561–585 (2010).

    Article  Google Scholar 

  39. Pfaus, J. G. Pathways of sexual desire. J. Sex. Med. 6, 1506–1533 (2009).

    Article  CAS  Google Scholar 

  40. Kingsberg, S. A. The testosterone patch for women. Int. J. Impot. Res. 17, 465–466 (2005).

    Article  CAS  Google Scholar 

  41. Clayton, A. H., Dennerstein, L., Pyke, R. & Sand, M. Flibanserin: a potential treatment for hypoactive sexual desire disorder in premenopausal women. Women's Health 6, 639–653 (2010).

    Article  CAS  Google Scholar 

  42. Thorp, J. et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J. Sex. Med. 9, 793–804 (2012).

    Article  CAS  Google Scholar 

  43. Derogatis, L. R. et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J. Sex. Med. 9, 1074–1085 (2012).

    Article  CAS  Google Scholar 

  44. Lenzer, J. Boehringer Ingelheim withdraws libido drug for women. BMJ 341, c5701 (2010).

    Article  Google Scholar 

  45. Labrie, F. et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 16, 907–922 (2009).

    Article  Google Scholar 

  46. van der Made, F. et al. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. J. Sex. Med. 6, 777–790 (2009).

    Article  CAS  Google Scholar 

  47. Petersen, C. D., Lundvall, L., Kristensen, E. & Giraldi, A. Vulvodynia. Definition, diagnosis and treatment. Acta Obstet. Gynecol. Scand. 87, 893–901 (2008).

    Article  CAS  Google Scholar 

  48. Brotto, L. A. et al. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol. Oncol. 125, 320–325 (2012).

    Article  Google Scholar 

  49. Brotto, L. A., Seal, B. N. & Rellini, A. Pilot study of a brief cognitive behavioral versus mindfulness-based intervention for women with sexual distress and a history of childhood sexual abuse. J. Sex Marital Ther. 38, 1–27 (2012).

    Article  Google Scholar 

  50. Cellek, S., Rees, R. W. & Kalsi, J. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. Expert Opin. Investig. Drugs 11, 1563–1573 (2002).

    Article  CAS  Google Scholar 

  51. Albersen, M., Shindel, A. W., Mwamukonda, K. B. & Lue, T. F. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin. Emerg. Drugs 15, 467–480 (2010).

    Article  CAS  Google Scholar 

  52. US National Library of Medicine. ClinicalTrials.gov [online], (2012).

  53. US National Library of Medicine. ClinicalTrials.gov [online], (2012).

  54. Oudot, A. et al. Combination of BAY 60–4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur. Urol. 60, 1020–1026 (2011).

    Article  CAS  Google Scholar 

  55. Claudino, M. A. et al. Long-term oral treatment with BAY 41–2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model. BJU Int. 108, 116–122 (2011).

    Article  CAS  Google Scholar 

  56. Shibuya, M. et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J. Neurosurg. 76, 571–577 (1992).

    Article  CAS  Google Scholar 

  57. Fujita, H. et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25, 144–149 (2010).

    Article  Google Scholar 

  58. Actelion reports arbitration results between subsidiary Cotherix, Inc. and Asahi Kasei Pharma Corporation. Actelion [online], (2009).

  59. US National Library of Medicine. ClinicalTrials.gov [online], (2011).

  60. Patel, M. V. et al. Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J. Med. Chem. 49, 7450–7465 (2006).

    Article  CAS  Google Scholar 

  61. US National Library of Medicine. ClinicalTrials.gov [online], (2009).

  62. Hakim, L., Van der Aa, F., Bivalacqua, T. J., Hedlund, P. & Albersen, M. Emerging tools for erectile dysfunction: a role for regenerative medicine. Nat. Rev. Urol. (in press).

  63. Melman, A. & Davies, K. Gene therapy for erectile dysfunction: what is the future? Curr. Urol. Rep. 11, 421–426 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cranfield Health, Cranfield University, Bedfordshire, MK43 0AL, UK

    Selim Cellek

  2. Sexological Clinic, Psychiatric Center Copenhagen, University of Copenhagen, Copenhagen, 2100, Denmark

    Annamaria Giraldi

Authors
  1. Selim Cellek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annamaria Giraldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors researched data for article, made a substantial contribution to discussion of content, wrote the manuscript and reviewed and edited the manuscript before submission.

Corresponding author

Correspondence to Selim Cellek.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cellek, S., Giraldi, A. Challenges in sexual medicine. Nat Rev Urol 9, 537–542 (2012). https://doi.org/10.1038/nrurol.2012.134

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2012.134

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research